AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Study to Evaluate P-Glucose, Safety and Tolerability After Oral Single Dosing of AZD6370 in Type 2 Diabetic Patients
- First Posted Date
- 2008-06-04
- Last Posted Date
- 2012-01-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT00690287
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
Study to Characterize the Long-term Clinical Experience of Atacand in Hypertensive Children Ages 1 to<11 Years (Hypertension in Pediatrics)
- First Posted Date
- 2008-06-04
- Last Posted Date
- 2011-07-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 35
- Registration Number
- NCT00690612
- Locations
- 🇺🇦
Research Site, Kyiv, Ukraine
AZD 2066 Single Dose Formulation and Food Effect Study in Healthy Volunteers
- First Posted Date
- 2008-06-04
- Last Posted Date
- 2010-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 20
- Registration Number
- NCT00690404
Study to Investigate the Safety, Tolerability and Pharmacokinetics of AZD1940
- First Posted Date
- 2008-06-04
- Last Posted Date
- 2010-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT00689780
- Locations
- 🇸🇪
Research Site, Upssala, Sweden
Study to Investigate the Safety, Tolerability and Pharmacokinetics of AZD1386
- First Posted Date
- 2008-06-04
- Last Posted Date
- 2010-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 69
- Registration Number
- NCT00690079
- Locations
- 🇬🇧
Research Site, Macclesfield, Cheshire, United Kingdom
Safety and Efficacy of Switching to Quetiapine in Outpatients With Schizophrenia
Completed
- Conditions
- Schizophrenia
- First Posted Date
- 2008-06-04
- Last Posted Date
- 2010-12-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 576
- Registration Number
- NCT00690365
Depressive Symptoms in Acute Manic Episode
Completed
- Conditions
- Bipolar Disorder
- First Posted Date
- 2008-06-04
- Last Posted Date
- 2010-12-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 250
- Registration Number
- NCT00690248
- Locations
- 🇪🇸
Research Site, Zaragoza, Spain
Tolerability/Safety of Intranasal AZD8848 in Healthy Male Volunteers and Seasonal Allergic Rhinitis Male Patients Out of Season
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2015-08-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 130
- Registration Number
- NCT00688779
- Locations
- 🇸🇪
Research Site, Lund, Sweden
Study to Investigate Safety and Tolerability of a Single Dose of AZD6482
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2008-06-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 49
- Registration Number
- NCT00688714
Study of Coronary Heart Disease (CHD) & Heart Failure (HF) Risk in Prostate Cancer Patients, Taking Casodex or Not
Completed
- Conditions
- Prostate Cancer
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2013-01-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5103
- Registration Number
- NCT00688532
© Copyright 2025. All Rights Reserved by MedPath